CJEU opinion on SPC referral is ‘overdue’, say lawyers
An opinion on whether a supplementary protection certificate can be granted to an owner of a drug patent when the marketing authorisation is held by a third party is overdue, lawyers told WIPR.
CMA accuses hydrocortisone suppliers of anti-competitive behaviour
The UK Competition and Markets Authority has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.
USITC to investigate Daewoong following Allergan complaint
The US International Trade Commission has begun an investigation into Daewoong Pharmaceuticals of South Korea and California-based Evolus, following a complaint from Allergan.
UK court overturns Genentech patent, cites Brexit in CJEU referral
The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.
US FTC settles pay-for-delay case with AbbVie
The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.
USITC investigating dental scanners for alleged patent infringement
The US International Trade Commission has begun an investigation into whether a Danish company’s dental and orthodontic scanners and software infringed an American company’s patents.
Patterson Belknap adds special counsel
Patterson Belknap Webb & Tyler has hired Barbara Mullin, a former lawyer at Akin Gump Strauss Hauer & Feld, as special counsel.
Judge orders Boehringer to disclose Humira biosimilar plans
A US judge has ordered Boehringer Ingelheim to release its rollout plans for a biosimilar version of Humira (adalimumab), following a request from AbbVie.
GE to sell biopharma unit to Danaher for $21.4 billion
General Electric (GE) will sell its biopharma business, which generated $3 billion in revenues for the conglomerate last year, to Danaher in a $21.4 billion deal.
Immunity can’t protect university from patent challenge: Fed Circuit
The US Court of Appeals for the Federal Circuit yesterday rejected the University of Florida’s argument that its sovereign immunity protected a patent from section 101 scrutiny.
